Substituted oxindole compounds
    65.
    发明授权
    Substituted oxindole compounds 有权
    取代的羟吲哚化合物

    公开(公告)号:US08486931B2

    公开(公告)日:2013-07-16

    申请号:US12529542

    申请日:2008-02-29

    摘要: The present invention relates to compounds of the general formula (I) in which A, B, R1, R2 and Het have the meaning given in claim 1; Y is a bivalent group of the formula in which D is C1-C3-alkylene, where D may have a substituent R5; R3 is hydrogen, C1-C8-alkyl or together with R4 is C1-C3-alkylene which may have a radical R5a, or together with R5 is C1-C3-alkylene, and R4 is hydrogen, C1-C8-alkyl or together with R3 is C1-C3-alkylene which may have a radical R5a, or together with R5 is C1-C3-alkylene, where R5 together with R5a, where present, are a bond or C1-C3-alkylene; and where one of the following conditions is satisfied: R3 together with R4 is C1-C3-alkylene which may have a radical R5a; or R3 together with R5 is C1-C3-alkylene; or R4 together with R5 is C1-C3-alkylene where the radical A is different from phenyl when the radical B is phenyl or naphthyl; and medicaments which comprise such compounds and the use thereof for the prophylaxis and/or treatment of vasopressin-dependent and/or oxytocin-dependent diseases.

    摘要翻译: 本发明涉及通式(I)的化合物,其中A,B,R1,R2和Het具有权利要求1中给出的含义; Y是下式的二价基团,其中D是C 1 -C 3 - 亚烷基,其中D可以具有取代基R 5; R 3是氢,C 1 -C 8烷基或与R 4一起是可以具有基团R 5a的C 1 -C 3亚烷基,或与R 5一起为C 1 -C 3 - 亚烷基,并且R 4是氢,C 1 -C 8 - 烷基或与 R 3是可以具有基团R 5a的C 1 -C 3亚烷基,或与R 5一起为C 1 -C 3 - 亚烷基,其中R 5与存在的R a a为键或C 1 -C 3 - 亚烷基; 并且其中满足以下条件之一:R 3与R 4一起可以具有基团R 5a的C 1 -C 3 - 亚烷基; 或R 3与R 5一起为C 1 -C 3 - 亚烷基; 或R 4与R 5一起为C 1 -C 3 - 亚烷基,其中基团B为苯基或萘基时,基团A不同于苯基; 以及包含这些化合物的药物及其用于预防和/或治疗加压素依赖性和/或催产素依赖性疾病的用途。

    N-[PIPERAZINYL HETARYL]ARYLSUFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR
    68.
    发明申请
    N-[PIPERAZINYL HETARYL]ARYLSUFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR 失效
    具有多巴胺D3受体亲和性的N- [哌嗪基]维生素A亚磺酰胺化合物

    公开(公告)号:US20110294817A1

    公开(公告)日:2011-12-01

    申请号:US13117269

    申请日:2011-05-27

    摘要: The invention related to N-[(piperazinyl)hetaryl]arylsulfonamide compounds of the general formula (I) in which Q is a bivalent, 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents Ra which is/are selected, independently of each other, from halogen, CN, NO2, CO2R4, COR5, C1-C4-alkyl and C1-C4-haloalkyl; Ar is phenyl or a 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents Rb, which is/are selected from halogen, NO2, CN, CO2R4, COR5, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C4-alkyl and C1-C4-haloalkyl, with it also being possible for two radicals Rb which are bonded to adjacent C atoms of Ar to be together C3-C4-alkylene; R1 is hydrogen, C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C4-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy-C1-C4-alkyl, C3-C4-alkenyl or C3-C4-alkynyl; with the radicals n, R1, R2, R3, R4 and R5 having the meanings given in the patent claims, to the N-oxides and to the physiologically tolerated acid addition salts of these compounds and to pharmaceutical compositions which comprise at least one N-[(piperazinyl)hetaryl]arylsulfonamide compound as claimed in one of claims 1 to 10 and/or at least one physiologically tolerated acid addition salt of I and/or an N-oxide of I, where appropriate together with physiologically acceptable carriers and/or auxiliary substances for treating diseases which respond to influencing by dopamine D3 receptor antagonists or agonists, in particular for treating diseases of the central nervous system and disturbances of kidney function.

    摘要翻译: 本发明涉及通式(I)的N - [(哌嗪基)杂芳基]芳基磺酰胺化合物,其中Q是具有1或2个N原子作为环成员的二价,6元杂芳族基团,并且任选地带有一个或两个 被卤素,CN,NO 2,CO 2 R 4,COR 5,C 1 -C 4 - 烷基和C 1 -C 4卤代烷基独立地选择的取代基R a; Ar是苯基或6元杂芳族基,其具有1或2个N原子作为环成员,并且任选地带有一个或两个选自卤素,NO 2,CN,CO 2 R 4,COR 5,C 1 -C 6 - 烷基,C 2 -C 6 - 烯基,C 2 -C 6 - 炔基,C 3 -C 6 - 环烷基,C 3 -C 6 - 环烷基-C 1 -C 4 - 烷基和C 1 -C 4卤代烷基, 与Ar的相邻C原子一起C3-C4-亚烷基; R 1是氢,C 1 -C 4烷基,C 1 -C 4卤代烷基,C 3 -C 6环烷基,C 3 -C 6环烷基-C 1 -C 4烷基,C 1 -C 4羟烷基,C 1 -C 4烷氧基-C 1 -C 4 - 烷基,C 3 -C 4 - 烯基或C 3 -C 4 - 炔基; 具有如专利权利要求中给出的含义的基团n,R 1,R 2,R 3,R 4和R 5与这些化合物的N-氧化物和生理上耐受的酸加成盐以及包含至少一种N- 和/或至少一种I的生理学耐受的酸加成盐和/或I的N-氧化物,其中适宜地与生理上可接受的载体和/或 用于治疗对多巴胺D3受体拮抗剂或激动剂影响的疾病的辅助物质,特别是用于治疗中枢神经系统疾病和肾功能障碍。